ArticleEvolution, medicine, and public health2018
Probing the evolutionary robustness of two repurposed drugs targeting iron uptake in
Article in Evolution, medicine, and public health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 34 citations in OpenAlex.
- EPS inhibitor treatment of Salmonella impacts evolution without selecting for resistance to biofilm inhibition.NPJ biofilms and microbiomes · 2025Article
- Escherichia coli growing under antimicrobial gallium nitrate stress reveals new processes of tolerance and toxicity.Scientific reports · 2025Article
- Antimicrobial activity of iron-depriving pyoverdines against human opportunistic pathogens.eLife · 2024Article
- Mechanisms of iron homeostasis in Pseudomonas aeruginosa and emerging therapeutics directed to disrupt this vital process.Microbial biotechnology · 2023Review
- Evolution-proof inhibitors of public good cooperation: a screening strategy inspired by social evolution theory.FEMS microbiology reviews · 2022Article
- Iron Homeostasis in Pseudomonas aeruginosa: Targeting Iron Acquisition and Storage as an Antimicrobial Strategy.Advances in experimental medicine and biology · 2022Article
- Review
- Antivirulence DsbA inhibitors attenuateFASEB bioAdvances · 2021Article
- Common Adaptive Strategies Underlie Within-Host Evolution of Bacterial Pathogens.Molecular biology and evolution · 2021Article
- Combining antibiotics with antivirulence compounds can have synergistic effects and reverse selection for antibiotic resistance in Pseudomonas aeruginosa.PLoS biology · 2020Article
- Harnessing bacterial interactions to manage infections: a review on the opportunistic pathogenJournal of medical microbiology · 2020Review
- Inhibiting bacterial cooperation is an evolutionarily robust anti-biofilm strategy.Nature communications · 2020Article
- Experimental evolution of gallium resistance inEvolution, medicine, and public health · 2019Article
- Activity and Impact on Resistance Development of Two Antivirulence Fluoropyrimidine Drugs inFrontiers in cellular and infection microbiology · 2019Article
- Novel Pyoverdine Inhibitors MitigateFrontiers in microbiology · 2018Article
- Pyocyanin Restricts Social Cheating inFrontiers in microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
lay summaryWe probed the evolutionary robustness of two antivirulence drugs, gallium and flucytosine, targeting the iron-scavenging pyoverdine in the opportunistic pathogen BACKGROUND AND
objectivesTreatments that inhibit the expression or functioning of bacterial virulence factors hold great promise to be both effective and exert weaker selection for resistance than conventional antibiotics. However, the evolutionary robustness argument, based on the idea that antivirulence treatments disarm rather than kill pathogens, is controversial. Here, we probe the evolutionary robustness of two repurposed drugs, gallium and flucytosine, targeting the iron-scavenging pyoverdine of the opportunistic human pathogen METHODOLOGY: We subjected replicated cultures of bacteria to two concentrations of each drug for 20 consecutive days in human serum as an
resultsWe found that mutants resistant against antivirulence treatments readily arose, but their selective spreading varied between treatments. Flucytosine resistance quickly spread in all populations due to disruptive mutations in CONCLUSIONS AND IMPLICATIONS: Our work highlights that antivirulence treatments are not evolutionarily robust
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.